|Dr. Vipin K. Garg Ph.D.||Pres, CEO & Director||869.46k||N/A||1958|
|Mr. Richard I. Eisenstadt M.B.A.||Chief Financial Officer||120k||N/A||1958|
|Dr. M. Scot Roberts Ph.D.||Chief Scientific Officer||564.87k||N/A||1959|
|Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS||Chief Medical Officer||614.11k||N/A||1953|
|Mr. Bertrand Georges Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Mr. Tony Blandin B.S.||VP of Quality & Compliance Management||N/A||N/A||N/A|
|Mr. José Ochoa||Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Kent A. Tapper BSEE||Corp. Controller||N/A||N/A||1957|
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.